Compare EH & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EH | TYRA |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2019 | 2021 |
| Metric | EH | TYRA |
|---|---|---|
| Price | $12.40 | $34.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $21.85 | ★ $44.63 |
| AVG Volume (30 Days) | 471.9K | ★ 729.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.53 | N/A |
| Revenue Next Year | $81.37 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.23 | $6.42 |
| 52 Week High | $25.79 | $35.71 |
| Indicator | EH | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 48.00 | 64.83 |
| Support Level | $11.23 | $20.86 |
| Resistance Level | $14.59 | N/A |
| Average True Range (ATR) | 0.43 | 2.50 |
| MACD | 0.14 | 0.32 |
| Stochastic Oscillator | 76.06 | 84.16 |
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.